Novasight Ltd. has scooped up $8 million in a series A financing that’s intended to get the company through a pivotal study of its first U.S. indication, Curesight, as well as to advance other pipeline products. The Israeli startup is tackling a range of pediatric vision disorders using artificial intelligence and eye-tracking technology.

A new $53 million in series C venture financing has bolstered Kernel's funding to further develop the company's brain recording technology and neuroscience as a service (NaaS) platform. The round was led by General Catalyst along with Khosla Ventures, Eldridge, Manta Ray Ventures, Tiny Blue Dot, and Kernel's CEO and founder Bryan Johnson.

HONG KONG – Chinese biotech giant Beigene Ltd. launched a $2.08 billion registered direct offering this week, the largest offering of its kind ever recorded globally. Beigene executives said net proceeds will primarily be used for general corporate purposes such as R&D for existing or new drugs in the pipeline.

Endpoint Health Inc. has made its official debut, scooping up $12 million in debt and equity financing from a host of investors, including Mayfield, Y Combinator, Ame Cloud Ventures and Wireframe Ventures. The Palo Alto, Calif.-based company is focused on helping people with illnesses such as sepsis and acute respiratory distress syndrome (ARDS) – life-threatening conditions often caused by serious infections, including COVID-19.

BEIJING – Beijing-based Immunotech Biopharm Ltd. made a strong debut as the first pre-revenue cellular immunotherapy firm to trade on the Hong Kong Stock Exchange (HKEX), raising $142 million via its IPO. Trading under the ticker 6978, the company’s share price closed at HK$15.48 (US$2) on July 10, up 40.7% from its offer price at HK$11.